Ginkgolide B inhibits non-small cell lung cancer cells by modulating the integrin β3 pathway.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
different doses of GB for 48 h
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
In vivo, GB treatment suppressed tumor growth, as well as suppressed the integrin β3 expression and the phosphorylation of the Akt/PI3K pathway. [CONCLUSIONS] GB inhibited NSCLC by inhibiting the integrin β3 pathway, providing a theoretical basis for the application of GB in NSCLC.
ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.9%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도
[OBJECTIVE] Ginkgolide B (GB) exhibits anti-tumor activity.
APA
Shao L, Song Z, et al. (2026). Ginkgolide B inhibits non-small cell lung cancer cells by modulating the integrin β3 pathway.. Toxicology and applied pharmacology, 511, 117806. https://doi.org/10.1016/j.taap.2026.117806
MLA
Shao L, et al.. "Ginkgolide B inhibits non-small cell lung cancer cells by modulating the integrin β3 pathway.." Toxicology and applied pharmacology, vol. 511, 2026, pp. 117806.
PMID
41921594 ↗
Abstract 한글 요약
[OBJECTIVE] Ginkgolide B (GB) exhibits anti-tumor activity. However, the inhibitory effect of GB on non-small cell lung cancer (NSCLC) and its specific molecular mechanisms remain unclear. This study aimed to analyze the pharmacological mechanism of GB for NSCLC.
[METHODS] Two NSCLC cells, A549 and H1299, were treated with different doses of GB for 48 h. Cell apoptosis, cell viability, and integrin β3 expression were measured to analyze the inhibitory effect of GB. The binding affinity between GB and integrin β3 was analyzed using microscale thermophoresis (MST). An integrin αβ blocker, LM609, was used as a positive control to analyze the effects of GB on integrin αβ. Meanwhile, the silence of integrin β3 (ITGB3) in NSCLC cells was established by ITGB3 siRNA transfection to analyze the role of integrin β3 in GB-mediated inhibition. Changes in cell viability, integrin β3, and the Akt/PI3K/mTOR pathway were measured. In A549-injected nude mice, animals were treated with GB or LM609 to observe the changes in tumor growth, integrin β3, and the Akt/PI3K pathway.
[RESULTS] GB treatment promoted the apoptosis of NSCLC cells, inhibited cell viability, and suppressed the integrin β3 expression in a dose-dependent manner. Meanwhile, a good binding affinity was found between GB and integrin β3. GB or LM609 treatment not only inhibited the integrin αβ expression but also suppressed the phosphorylation of the Akt/PI3K pathway. Meanwhile, the silence of integrin β3 attenuated the GB-induced effects. In vivo, GB treatment suppressed tumor growth, as well as suppressed the integrin β3 expression and the phosphorylation of the Akt/PI3K pathway.
[CONCLUSIONS] GB inhibited NSCLC by inhibiting the integrin β3 pathway, providing a theoretical basis for the application of GB in NSCLC.
[METHODS] Two NSCLC cells, A549 and H1299, were treated with different doses of GB for 48 h. Cell apoptosis, cell viability, and integrin β3 expression were measured to analyze the inhibitory effect of GB. The binding affinity between GB and integrin β3 was analyzed using microscale thermophoresis (MST). An integrin αβ blocker, LM609, was used as a positive control to analyze the effects of GB on integrin αβ. Meanwhile, the silence of integrin β3 (ITGB3) in NSCLC cells was established by ITGB3 siRNA transfection to analyze the role of integrin β3 in GB-mediated inhibition. Changes in cell viability, integrin β3, and the Akt/PI3K/mTOR pathway were measured. In A549-injected nude mice, animals were treated with GB or LM609 to observe the changes in tumor growth, integrin β3, and the Akt/PI3K pathway.
[RESULTS] GB treatment promoted the apoptosis of NSCLC cells, inhibited cell viability, and suppressed the integrin β3 expression in a dose-dependent manner. Meanwhile, a good binding affinity was found between GB and integrin β3. GB or LM609 treatment not only inhibited the integrin αβ expression but also suppressed the phosphorylation of the Akt/PI3K pathway. Meanwhile, the silence of integrin β3 attenuated the GB-induced effects. In vivo, GB treatment suppressed tumor growth, as well as suppressed the integrin β3 expression and the phosphorylation of the Akt/PI3K pathway.
[CONCLUSIONS] GB inhibited NSCLC by inhibiting the integrin β3 pathway, providing a theoretical basis for the application of GB in NSCLC.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- A radiomics model for preoperative prediction of microvascular invasion as a factor in predicting prognosis of hepatocellular carcinoma after radiofrequency ablation.
- Mitochondria-targeted CORM-401 nanoparticles inhibit A549 cells by triggering cuproptosis.
- An MRI-pathology foundation model for noninvasive diagnosis and grading of prostate cancer.
- DKK1-SE recruits AP1 to activate the target gene DKK1 thereby promoting pancreatic cancer progression.
- Risk factors associated with preferential lateral lymph node metastasis in papillary thyroid carcinoma.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Role of Cytokines in Oligometastatic Non-Small-Cell Lung Cancer Treated with Stereotactic Radiation Therapy: An Observational Pilot Study.
- Development and validation of a novel nomogram model for predicting postoperative survival of T4N0M0 NSCLC: a population-based survival analysis.
- Cost comparison of osimertinib plus platinum-pemetrexed versus amivantamab plus lazertinib for the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.
- RBM15 Mediated m6A Modification of SRSF1 Inhibits Cuproptosis in Non-Small Cell Lung Cancer by Mediating ATP7B Alternative Splicing.
- DIP-like Adenocarcinoma Presenting as a Part-Solid Nodule: A Case Report.
- Targeting Mesenchymal-Epidermal Transition (MET) Aberrations in Non-Small Cell Lung Cancer: Current Challenges and Therapeutic Advances.